Both FAM26F and RGS10, whose expression correlated with poor clinical outcome, were found significantly enriched in AML with t(7;12) (MNX1/ETV6) and t(8;21) (RUNX1/RUNX1T1) (Fig. 6a, b) whereas expression of CD48 did not correlate with any AML subtype (Fig. 6c). This evidence concerns the gene ETV6 and acute myeloid leukemia.